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Hemojuvelin (HJV) isaglycosylphosphatidylinositol-linkedpro-
tein and binds both bone morphogenic proteins (BMPs) and neo-
genin.CellularHJVacts as aBMPco-receptor to enhance the tran-
scription of hepcidin, a key iron regulatory hormone secreted
predominantly by liver hepatocytes. In this studywe characterized
the role of neogenin in HJV-regulated hepcidin expression. Both
HJV and neogenin were expressed in liver hepatocytes. Knock-
down of neogenin decreased BMP4-induced hepcidin mRNA
levels by 16-fold in HJV-expressing HepG2 cells but only by
about 2-fold in cells transfected with either empty vector or
G99V mutant HJV that does not bind BMPs. Further studies
indicated that disruption of the HJV-neogenin interaction is
responsible for a marked suppression of hepcidin expression.
Moreover, in vivo studies showed that hepatic hepcidin mRNA
could be significantly suppressed by blocking the interaction of
HJV with full-length neogenin with a soluble fragment of neo-
genin inmice. Together, these results suggest that theHJV-neo-
genin interaction is required for the BMP-mediated induction
of hepcidin expression when HJV is expressed. Combined with
our previous studies, our results support that hepatic neogenin
possesses two functions, mediation of cellular HJV release, and
stimulation of HJV-enhanced hepcidin expression.
Iron is an indispensable nutrient required for a variety of
biochemical processes such as respiration, metabolism, and
DNA synthesis. Iron homeostasis in the body is regulated pri-
marily by the rate of iron absorption from the intestine.
Mutations in the key iron homeostatic proteins result in
either hereditary hemochromatosis or iron-deficient anemia
(1–4). Hereditary hemochromatosis is a heterogeneous group
of inherited iron overload disorders linked to mutations in sev-
eral genes including HFE, HFE2, HAMP (the hepcidin gene),
and TFR2.HFE2 is a recently cloned gene encoding the protein
hemojuvelin (HJV)2 (5). Both theHFE2mRNA and protein are
highly expressed in skeletal muscles and the heart and at lower
levels in the liver (5, 6).
HJV plays a pivotal role in iron homeostasis. Homozygous or
compound heterozygous mutations in HFE2 are the major
cause of juvenile hemochromatosis (5), a particularly severe
form of hereditary hemochromatosis (7, 8). The marked sup-
pression of hepatic hepcidin expression observed in juvenile
hemochromatosis patients with HFE2 mutations as well as in
HJV knock-out (Hjv/) mice has implicated HJV as a critical
upstream regulator of hepcidin transcription (5, 9, 10). Hepci-
din, the key iron regulatory hormone, is predominantly
expressed in liver hepatocytes, and iron levels in the body pos-
itively regulate its expression (11, 12). In the liver HJV is found
predominantly in hepatocytes (10), where it regulates hepcidin
expression.
HJV is a glycosylphosphatidylinositol-linked membrane-
bound protein and is either associated with cells or released by
proteolytic cleavage in a soluble form. Cellular HJV acts as a
co-receptor for bone morphogenic proteins (BMPs), BMP2,
BMP4, BMP5, and BMP6 to enhance the transcription of hep-
cidin through the BMP-signaling cascade (13, 14). Binding of
BMP ligands to BMP receptor complexes on the cell surface
triggers the phosphorylation of Smad1, Smad5, and Smad8
(Smad1/5/8) in the cytoplasm. The phosphorylated Smads
(pSmad1/5/8) form heteromeric complexes with Smad4 and
then translocate into the nucleus where they induce the tran-
scription of target genes (15). Liver-specific disruption of
Smad4 in mice markedly decreases hepcidin expression and
causes severe iron accumulation in different organs, further
supporting the pivotal role of BMP signaling in the regulation of
hepcidin expression (16).
HJV cleavage and subsequent release constitutes the major
pathway of cellular HJV turnover in HepG2 cells transfected to
express HJV (17). Functional studies reveal that soluble HJV
suppresses BMP-induced hepcidin expression both in vitro and
when injected intomice, likely through competitionwithmem-
brane-associated HJV for limited BMPs (14, 18). Previous stud-
ies suggest that HJV release may involve retrograde trafficking
of HJV from the plasma membrane to the Golgi/trans-Golgi
network compartment, where it may be subjected to cleavage
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by the proprotein convertase furin, followed by rapid release
from cells (17, 19, 20). Interaction of HJV with neogenin, a type
I membrane protein expressed in most tissues including the
liver (21), is required for HJV release from different cell lines
(6, 17).
In this study we characterized the role of neogenin in HJV-
regulated hepcidin expression. Our results indicated that HJV
and neogenin are co-expressed in liver hepatocytes. Surpris-
ingly, the HJV-neogenin interaction is required for the induc-
tion of hepcidin expression by BMP4 in addition to its role of
mediating HJV release from cells.
EXPERIMENTAL PROCEDURES
Quantitative Real-time RT-PCR (qRT-PCR)—qRT-PCR was
used to analyze the mRNA levels of HFE2, neogenin, and
GAPDH in isolated rat liver hepatocytes, Kupffer cells, sinusoi-
dal endothelial cells, and hepatic stellate cells (HSC) as well as
the mRNA levels of hepcidin and GAPDH in HepG2 cells and
mouse livers. Total RNA isolation and cDNA preparation were
previously described (22). qRT-PCR analysis was performed
using primers specific for rat genes and humanGAPDH as pre-
viously reported (6, 22, 23). The sequences of other primers are
5-ggctctgttttcccacaacag-3 (forward, human hepcidin), 5-tcc-
ttcgcctctggaacatgg-3 (reverse, human hepcidin), 5-aaatatgac-
aactcactcaagattgtca-3 (forward, mouse GAPDH), 5-cccttcca-
caatgccaaagt-3 (reverse, mouse GAPDH), 5-ctgagcagcaccac-
ctatctc-3 (forward, mouse hepcidin), and 5-tggctctaggctatgt-
tttgc-3 (reverse, mouse hepcidin). The results for each gene of
interest are expressed as the amount relative to that of GAPDH
in each sample.
Cell Culture and Transfection—HepG2 cells were purchased
from ATCC and maintained in MEM, 10% FCS, 1 mM pyru-
vate/1 nonessential amino acids (complete medium). HepG2
cells stably expressing G99V HJV (G99V-HepG2) were gener-
ated using the Nucleofector kit V (Amaxa Biosystems) as pre-
viously described (6). HepG2 cells stably transfected with wild
type HFE2 (HJV-HepG2) or pcDNA3 empty vector (control-
HepG2) were generated previously (6, 24). The stably trans-
fected cells were maintained in complete medium with 800
g/ml G418.
HepG2 cells stably transfected with the tetracycline repres-
sor (tTA-HepG2) were obtained from Dr. Gregory Longmore
atWashington University, St. Louis (25). tTA-HepG2-HJV and
tTA-HepG2-G99V HJV cells were generated by subcloning
HFE2 or G99V HFE2 cDNA into a tetracycline-inducible
pcDNA4 vector, respectively, followed by a stable transfection
into tTA-HepG2 cells. Transfected cells were maintained in
complete medium with 800 g/ml G418 and 5 g/ml blastici-
din and induced to express HJV using 2 g/ml doxycycline
(dox), a tetracyline homolog. tTA-HepG2 cells transfectedwith
empty pcDNA4 vector (tTA-HepG2-control) were also gener-
ated and used as controls.
Mutagenesis—TheG99VmutantHFE2 cDNAwas generated
using theQuikChangeTMXL site-directedmutagenesis kit (Strat-
agene) following themanufacturer’s instructions. pcDNA3-HFE2
construct was used as a template. The primers used to intro-
duce the mutation were 5-ccgcacctgccgcgtggacctcgccttcc-3
(forward) and 5-ggaaggcgaggtccacgcggcaggtgcgg-3 (reverse).
Themutation in the resulting constructwas confirmed byDNA
sequencing. No other sequence change was detected.
BMP4 Treatment—tTA-HepG2-HJV, -G99V HJV, or -con-
trol cells were subcultured into 12-well plates. After 48 h of
incubation, cells at about 60% confluence were incubated with
MEM, 1 mM pyruvate, 1 nonessential amino acids (NEAA),
1% FCS plus 2g/ml dox for 6 h to serum starve the cells and to
induce HJV expression. Cells were then incubated in the same
medium with BMP4 (R&D Systems, Inc.) at the indicated con-
centrations for the time intervals described in each figure leg-
end. In some studies 40 nM soluble neogenin fibronectin type III
5–6 domain (Neo FNIII 5–6) or 5 M decanoyl-Arg-Val-Lys-
Arg-chloromethyl ketone (Alexis Biochemicals), a furin con-
vertase inhibitor (FCI), was also included. For Western blot
analysis, the conditioned medium (CM) was collected, and cell
lysate was prepared for the immunodetection of HJV in both
CM and lysate as well as for the immunodetection of phospho-
rylated Smad1/5/8 (pSmad) and-actin in the lysates. For qRT-
PCR analysis of hepcidin and GAPDH mRNA, total cellular
RNA was isolated as described under “Quantitative Real-time
RT-PCR.” Neo FNIII 5–6 fragment specifically binds HJV with
a KD in the subnanomolar range. Purified Neo FNIII 5–6 was
generated from baculovirus as previously described (26).
Knockdown of Endogenous Neogenin—SMARTpool siRNA
specific for human neogenin (Dharmacon) was used to knock
down the endogenous neogenin in control-, HJV-, and G99V
HJV-HepG2 cells as previously described (6). RNAiMAX rea-
gent (Invitrogen) was used for the transfection. The negative
control siRNAwas previously described (6). siRNA transfection
was conducted in 12-well plates in complete medium. About
48-h after transfection, cells were serum-starved with MEM, 1
mMpyruvate, 1NEAA, 1% FCS for 6 h followed by incubation
with the samemedium (1ml perwell) supplementedwith 0, 0.5,
1, and 5 ng/ml BMP4 for 16 h. CM was then collected, and cell
lysate was prepared for immunodetection. Total cellular RNA
was isolated for qRT-PCR analysis.
For neogenin rescue studies HJV-HepG2 cells were first
transfected with either control or neogenin siRNA. On the fol-
lowing day cells were transfected with either human neogenin
cDNA or pcDNA3 empty vector using FuGENE HD transfec-
tion reagent (Roche Applied Science). On day 3, cells were
serum-starved with MEM, 1 mM pyruvate, 1 NEAA, 1% FCS
for 6 h followed by incubation with the samemedium (1 ml per
well) supplemented with 5 ng/ml BMP4 for 16 h. About 72 h
after the siRNA transfection, CM was collected, cell lysate was
prepared for immunodetection, and total RNAwas isolated for
qRT-PCR analysis.
Flow Cytometry—Flow cytometry was used to quantify cell
surface HJV in HJV-HepG2 cells after treatment with or with-
out 40 nM Neo FNIII 5–6 for 16 h as well as in G320V HJV,
D172E HJV, and G99V HJV-HepG2 cells. Cells were detached
from flasks with cell dissociation buffer (Invitrogen). Cells were
then incubated with affinity-purified rabbit anti-HJV antibody
(4 g/ml) in Hanks’ buffer supplemented with 3% fetal bovine
serum for 30 min at 4 °C, washed, and incubated with phyco-
erythrin-conjugated goat anti-rabbit IgG (1:500 dilution)
(Caltag, Burlingame, CA) in the same buffer for 30 min at 4 °C.
Flow cytometry analysis was performed on a BD Biosciences
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FACSCalibur flow cytometer. Rabbit IgG and control-HepG2
cells were used as negative controls. The levels of cell surface
HJV are expressed as arbitrary units (6).
Immunodetection—Cell lysates from the isolated rat liver
cells and HepG2 cells were prepared using NET-Triton (150
mM NaCl, 5 mM EDTA, 10 mM Tris (pH 7.4), and 1% Triton
X-100) supplemented with 1 protease inhibitor mixture
(Roche Applied Science), 1 mM sodium fluoride (Sigma), and 1
mM sodium orthovanadate (Sigma). Proteins from the isolated
liver cells (250 g), whole cell extract from 1 well of a 12-well
plate, and conditioned medium (120 l) were separated using
11% SDS-PAGE under reducing conditions followed by trans-
fer onto nitrocellulose membrane. Membranes were probed
with affinity-purified rabbit anti-HJV antibody (0.22 g/ml)
(21), rabbit anti-neogenin antibody (0.4g/ml, Santa Cruz Bio-
technology), rabbit anti-phosphorylated Smad1/5/8 (1:1,000;
Cell Signaling Technology), or mouse anti--actin antibody
(1:10,000; Chemicon International, Temecula, CA) followed
by immunodetection using corresponding horseradish peroxi-
dase-conjugated secondary antibodies (Chemicon Interna-
tional). The chemiluminescent bands were exposed to x-ray
film (Super Signal, Pierce).
Neo FNIII 5–6 Injection—Eight-week-old male 129EvSv
mice were injected intraperitoneally with purified Neo FNIII
5–6 at 3 mg/kg body weight or carrier buffer twice on the same
day at 8:30 a.m. and 3:30 p.m. Injected mice had free access to
the regular rodent diet. At 24 h after the first injection, animals
were euthanized while under anesthesia. Liver tissues were col-
lected for qRT-PCR analysis of hepcidin and GAPDH mRNA.
Each group consisted of three mice. All the procedures were
approved by the Institutional Animal Care and Use Committee
of Oregon Health and Science University.
Statistical Analysis—The S.D. and the paired two-tailed Stu-
dent’s t test were used to compare two sets of data. The one-way
analysis of variance andTukey’s post-test were used to compare
three or more sets of data.
RESULTS
HJV and Neogenin Are Co-expressed in Hepatocytes—We
sought to explore the role of neogenin in HJV-regulated hepci-
din expression in hepatocytes in vivo because previous studies
demonstrated that HJV binds neogenin and that the HJV-neo-
genin interaction is required for HJV release (11, 21, 22). We
first examined the expression profiles of HFE2 and neogenin
mRNA and proteins in the liver using isolated rat liver hepato-
cytes, Kupffer cells, sinusoidal endothelial cells, andHSC. Con-
sistent with findings in a previous report (10), both HFE2
mRNA and protein were detected predominantly in hepato-
cytes (Fig. 1, A and C). In contrast, both neogenin mRNA and
protein were detected in all liver cell populations (Fig. 1, B and
C). The highest level of neogenin mRNA was found in HSC,
3.7-, 12.9-, and 7.3-fold greater than in hepatocytes,
Kupffer cells, and sinusoidal endothelial cells, respectively (Fig.
1B). Immunoblots revealed a similar profile of neogenin protein
expression (Fig. 1C, upper panel). In the liver, hepatocytes
account for approximate 65% in cell number and 80% in vol-
ume, but HSCs only account for approximate 5–8% in cell
number and 1.4% in volume (27). Therefore, these results sug-
FIGURE 1. HFE2 and neogenin expression profiles in isolated rat liver
cells.A, qRT-PCRanalysis ofHFE2mRNA in isolated rat liver hepatocytes (Hep,
n 5), Kupffer cells (KC, n 7), sinusoidal endothelial cells (SEC, n 4), and
hepatic stellate cells (HSC, n 6). Results are expressed as the amounts rela-
tive to GAPDH. The mean values and the S.D. for each cell population are
presented. B, qRT-PCR analysis of neogenin mRNA in isolated rat liver cell
populations. The analysis was performed as described in A. C, Western blot
analysis of HJV and Neo proteins in isolated rat liver cells. Cell extract protein
(250 g) was separated in SDS-PAGE under reducing conditions. Equal pro-
tein loading was confirmed by Ponceau S staining of the membrane (not
shown).Membraneswere probedwith antibodies against HJV andneogenin.
Cell lysate from HEK293 cells stably expressing both HJV and neogenin (HEK)
was included as a positive control. Experiments were performed using two
different sets of isolated cells and showed consistent results.
Neogenin and Hepcidin Expression
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gest that hepatocytes are also themajor site of neogenin expres-
sion in the liver.
In situ hybridization and immunohistochemistry analysis
revealed that both HFE2 mRNA and protein were evenly
detected in hepatocytes in rat liver tissues with no evidence of a
zonal distribution (supplemental Fig. 1, A and B). Neogenin
mRNA and protein were observed in hepatocytes as well as in
non-parenchymal cells throughout the liver tissues (supple-
mental Fig. 1,A andB). Together, the above results indicate that
HJV and neogenin are co-expressed in hepatocytes.
BMP4 Induces Hepcidin Expression in HepG2 Cells—Hepci-
din expression is induced via the BMP-signaling cascade (13,
16). We wanted to use the hepatoma cell lines HepG2 cells
and tTA-HepG2 cells, where proteins can be expressed in a
tetracycline-dependent manner, as model systems to deter-
mine the role of neogenin in HJV-regulated hepcidin expres-
sion. They are relatively differentiated hepatoma cell lines that
express hepcidin, neogenin (24), and many other hepatocyte-
specific genes but have no detectable HJV protein by Western
blot analysis (data not shown). HFE2 mRNA levels are close to
the limit of detection by qRT-PCR and are about 1300-fold
lower than in human liver tissue (data not shown).
We first titrated the response of tTA-HepG2 cells to BMP4, a
ligand for both HJV and BMP receptors that is expressed in the
liver (14, 28). Induction of hepcidin could be detectable at as
low as 0.1 ng/ml BMP4 as measured by qRT-PCR. Increases in
hepcidin mRNA of 1.8-, 3.5-, 13.4-, 130-, 212-, 310-, and 371-
fold were detected with the addition of 0.1, 0.5, 1, 5, 10, 25, and
50 ng/ml BMP4, respectively. The induction was nearly linear
up to 5 ng/mlBMP4when cellswere treatedwithBMP4 for 18 h
(Fig. 2). On the basis of these observations, a concentration of 5
ng/ml BMP4 was chosen for our studies. At 5 ng/ml BMP4,
hepcidin mRNA levels were increased by 130-fold in tTA-
HepG2 cells, indicating that BMP4 can induce hepcidin tran-
scription independently of HJV. These results are consistent
with previous studies showing that BMP2 induces hepcidin
expression in the primary hepatocytes isolated from Hjv/
mice (13). HepG2 cells are, thus, an appropriate cell line to
study the effects of neogenin and different constructs ofHJV on
hepcidin expression.
Knockdown of Neogenin Suppresses Hepcidin Expression
Markedly When HJV Is Expressed—Soluble HJV suppresses
BMP-induced hepcidin expression through competition with
membrane-associated HJV for a limited BMP supply (14, 18).
We wanted to test the hypothesis that neogenin negatively reg-
ulates hepcidin expression by facilitating the release of HJV
from cells as shown previously (24). Endogenous neogenin was
knocked down in HepG2 cells stably transfected with HFE2
(HJV) or empty vector (control). The responses of BMP signal-
ing and hepcidin expression to BMP4 treatment were then
examined.
First, we tested the effects of neogenin knockdown on BMP
signaling and hepcidinmRNA in the presence of 5 ng/ml BMP4
(Fig. 3, A and B). A single transfection of neogenin siRNA sig-
nificantly decreased the levels of endogenous neogenin in con-
trol and HJV-HepG2 cells (Fig. 3A, top panel). The accumula-
tion of cellularHJVdetected inHJV-HepG2 cellswith neogenin
knockdown (Fig. 3A) is consistent with a previous study, in
which a soluble neogenin whole ectodomain that binds HJV
was used to block HJV release (17). HJV-HepG2 cells have
lower base-line levels of pSmad than control-HepG2 cells (Fig.
3A). Because HepG2 cells were stably transfected with HJV and
clonally selected, differences in basal levels in the selected
clones could account for this observation.
Contrary to our initial hypothesis, neogenin knockdown
resulted in a 16-fold decrease, rather than an increase, in
hepcidin mRNA in HJV-HepG2 cells and about a 2-fold
decrease in control-HepG2 cells compared with their corre-
sponding controls (Fig. 3B). Because hepcidin expression is
induced by the BMP-signaling pathway (13, 16), the results of
hepcidin mRNA were verified by examining the effects of neo-
genin knockdown on BMP signaling. Levels of phosphorylated
Smad1/5/8 (pSmad) are a direct indicator of BMP receptor acti-
vation. In agreement with the reduced induction of hepcidin
mRNA, immunoblots revealed decreased pSmad in neogenin-
depleted cells (Fig. 3A). Therefore, these results suggest that the
suppression of hepcidin expression in both control and HJV-
HepG2 cells after neogenin knockdown results from decreased
BMP signaling.
To determine whether the inhibition is BMP4-dependent,
we next examined the effects of neogenin knockdown on
hepcidin expression in HJV-HepG2 cells with the addition of
0, 0.5, and 1 ng/ml concentrations of exogenous BMP4. A
similar level of inhibition was obtained under each condition
(Fig. 3C). These results indicate that when HJV is expressed,
the suppression of hepcidin expression by neogenin knock-
down is independent of the addition of exogenous BMP4.
Because the levels of HJV mRNA in the control-HepG2 cells
FIGURE 2. Titration of the response of hepcidin mRNA expression to
BMP4. tTA-HepG2 cells were subcultured into 12-well plates. After 48 h of
incubation, cells at about 60% confluence were first incubated with MEM, 1
mM pyruvate, 1 NEAA, 1% FCS for 6 h to serum starve the cells. Cells were
then incubated in the samemediumwith BMP4 at 0, 0.1, 0.5, 1, 5, 10, 25, and
50 ng/ml for 18 h followed by total RNA isolation, cDNA preparation, and
qRT-PCR analysis of hepcidin and GAPDH mRNA. The hepcidin mRNA levels
are expressed as the amount relative to that of GAPDH in each specific sam-
ple. The results are from three separate experiments, and the mean values
and the S.D. are presented.
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are negligible compared with human liver tissues or HJV-
HepG2 cells (data not shown), these results suggest that in
the presence of no or very low levels of HJV, neogenin acts to
maintain the basal levels of BMP signaling, and the resulting
hepcidin expression. In contrast, the marked suppression of
hepcidin expression detected in HJV-HepG2 cells depleted
of neogenin implies that when HJV is expressed, neogenin is
required for full extent of the induction of hepcidin expres-
sion by BMP4.
To rule out the possibility that the inhibitory effect detected
in neogenin-depleted HJV-HepG2 cells results from an off-tar-
get effect, we conducted a neogenin rescue study. Transfection
of cells with neogenin after endogenous neogenin knockdown
was able to partially rescue the HJV release (Fig. 3D, left panel)
as well as the hepcidin expression (Fig. 3D, right panel) induced
by BMP4 at 5 ng/ml. The lack of a complete rescue might be
because of the low transfection efficiency of neogenin cDNA.
These results, therefore, suggest that the effect of neogenin
FIGURE3.Knockdownofneogenin suppressesBMP4-inducedhepcidinexpression.A, knockdownofneogenindecreasespSmad1/5/8. Control-, HJV-, and
G99VHJV-HepG2 cells in 12-well plateswere transfectedwith either control (Ctrl) or neogenin (Neo) siRNAusing RNAiMAX reagent. After about 48 h, cellswere
serum-starved for 6 h followed by incubation with the same medium (1 ml/well) supplemented with 5 ng/ml BMP4 for 16 h. CM was then collected, and cell
lysate was prepared. About 15% of CM and the total lysate were subjected to SDS-PAGE followed by immunodetection of neogenin (Neo), pSmad1/5/8
(pSmad), HJV, and -actin in the lysate (L) and HJV in CM. B, knockdown of neogenin decreases the BMP4-induced hepcidinmRNA. Neogenin knockdown and
BMP4 treatment in control-, HJV-, andG99VHJV-HepG2 cellswereperformed in essentially the samemanner as described inA. Total RNAwas isolated followed
by cDNA preparation and qRT-PCR analysis of hepcidin and GAPDHmRNA. The hepcidin mRNA levels are expressed as the amount relative to that of GAPDH
in each specific sample. C, knockdown of neogenin decreases hepcidin mRNA in the absence of exogenous BMP4. All the experimental procedures were
performed as described in B except that control- and HJV-HepG2 cells were incubated with different concentrations of BMP4 (0, 0.5, 1, and 5 ng/ml). D, neo-
genin rescue analysis. HJV-HepG2 cells were first transfectedwith either control (Ctrl) or neogenin (Neo) siRNAonday 1. About 24 h later, cells were introduced
with either human neogenin cDNA (hNeo) or pcDNA3 empty vector (pcDNA3). On day 3, cells were serum-starvedwithMEM, 1mMpyruvate, 1NEAA, 1% FCS
for 6 h followedby incubationwith the samemedium (1ml/well) supplementedwith 5 ng/ml BMP4 for 16 h. At about 72 h after the siRNA transfection, CMwas
collected, and cell lysate was prepared for immunodetection (left panel) as well as for qRT-PCR analysis of hepcidinmRNA (right panel) as described in A and B,
respectively. All the experiments were repeated at least three times with consistent results. The qRT-PCR results in B andDwere assessed by one-way analysis
of variance, and the statistical significant differences relative to the corresponding controls were determined by Tukey’s post-test. *, p 0.05; **, p 0.01; ***,
p 0.001.
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knockdown in HJV-HepG2 cells is not caused by an off-target
effect.
HepG2 cells have higher basal levels of hepcidin mRNA than
tTA-HepG2 cells (Fig. 3B versus Fig. 2). tTA-HepG2 cells were
derived by selecting a clone of HepG2 cells stably transfected
with the tTA tetracycline repressor (25) and, thus, could
account for the lower basal levels of hepcidin than the parent
cell line.
Neogenin Knockdown Does Not Markedly Suppress Hepcidin
Expression when G99V HJV Is Expressed—HJV can simulta-
neously bind both BMP2 and neogenin (26). G99Vmutant HJV
is a non-functional form of HJV. In humans G99V substitution
in HJV causes juvenile hemochromatosis (5). G99V HJV binds
neogenin (supplemental Fig. 2A) but not BMPs (29). To deter-
mine whether or not the suppression of hepcidin expression
detected in HJV-HepG2 cells after neogenin knockdown is
because of the disruption of the HJV-neogenin interaction, we
next examined the effect in HepG2 cells stably expressing the
G99V mutant HJV. Because the interaction with neogenin is
required for HJV release (6), G99V HJV behaved similarly to
wild type HJV in its active release and plasma membrane
expression (supplemental Fig. 2, B and C). Similar to HJV-
HepG2 cells, neogenin knockdown blocked the release of G99V
HJV from G99V HJV-HepG2 cells (Fig. 3A). However, in con-
trast to themarked suppression of hepcidin expression in HJV-
HepG2 cells, knockdown of neogenin knockdown in G99V
HJV-HepG2 cells only caused a mild decrease in hepcidin
mRNA,which is similar to that in control-HepG2 cells (Fig. 3B).
Together with the findings in both control and HJV-HepG2
cells, our results imply that neogenin dictates the extent of the
induction of hepcidin expression onlywhen it is associatedwith
a functional HJV that can bind BMPs.
Blockage of HJV Release by a Furin Convertase Inhibitor Does
Not Suppress BMP4-induced Hepcidin Expression—Because
neogenin is not necessarily required for HJV trafficking to the
plasma membrane (24), the dramatic suppression of BMP4-
induced hepcidin expression in HJV-HepG2 cells with neoge-
nin knockdown could result from either the inhibition of HJV
release or the lack of HJV-neogenin association. To determine
which of these processes is required for the induction of hepci-
din expression, we first examined the role of HJV release in
BMP4-induced hepcidin expression in tTA-HepG2-HJV cells,
in which the expression of HJV was induced by the addition of
dox. HJV release is mediated via cleavage by the proprotein
convertase, furin (19, 20). tTA-HepG2-HJV cells were incu-
bated with BMP4 to induce BMP signaling in the absence or
presence of 5MFCI, which blocks the release ofHJV. Blockage
of HJV release by FCI mildly increased the levels of pSmad
protein (Fig. 4A) and hepcidin mRNA (Fig. 4B). This is consist-
ent with previous observations that soluble HJV suppresses
BMP-induced hepcidin expression (14, 18). Thus, the suppres-
sion of hepcidin expression observed inHJV-HepG2 cells when
neogenin expression is down-regulated does not result from
the inhibition of HJV release.
Disruption of theHJV-Neogenin Interaction by a Soluble Neo-
genin Fragment SuppressesBMP4-inducedHepcidinExpression—
The binding of neogenin toHJVmaps to the fibronectin type III
5–6 domain (Neo FNIII 5–6) in the extracellular domain of
neogenin (26). HJV can simultaneously bind both BMP2 and
neogenin, suggesting that the binding sites do not overlap (26).
To determine the effect of the HJV-neogenin interaction on
BMP4-induced hepcidin expression, purified Neo FNIII 5–6
fragment was used to disrupt the interaction of HJV with the
endogenously expressed full-length neogenin. tTA-HepG2
cells were used as a model system in which the expression of
HJV or G99VHJVwas under the control of tetracycline-induc-
ible promoter. tTA-HepG2 cells stably transfected with wild
FIGURE 4. Inhibition of HJV release by a furin convertase inhibitor does
not suppressBMP4-inducedhepcidinexpression.A,Westernblot analysis.
tTA-HepG2 cells stably expressing HJV or transfectedwith empty vector (Ctrl)
were maintained in the absence of dox. At about 48 h after subculturing into
12-well plates, cells were first incubatedwithMEM, 1mMpyruvate, 1NEAA,
1% FCS plus 2 g/ml dox for 6 h to serum starve the cells and to induce HJV
expression. Cells were then incubated in the same medium containing 5
ng/ml BMP4 with or without 5 M decanoyl-Arg-Val-Lys-Arg-chloromethyl
ketone, a FCI, for 18 h. CM was collected, and cell lysates were prepared.
About 20% of CM and the total lysate were subjected to SDS-PAGE followed
by immunodetection of pSmad1/5/8 (pSmad), HJV, and -actin in the lysate
(L) and HJV in CM. This experiment was repeated three times with consistent
results. B, qRT-PCR analysis of hepcidinmRNA. Incubation of tTA-HepG2-con-
trol and -HJV cells with FCI and BMP4 was performed in essentially the same
manner as described in A. Total RNAwas isolated followed by cDNA prepara-
tionandqRT-PCRanalysis of hepcidin andGAPDHmRNA. ThehepcidinmRNA
levels are expressed as the amount relative to that of GAPDH in each specific
sample. The results are from four separate experiments, and themean values
and the S.D. are presented.
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type HFE2 (tTA-HepG2-HJV), G99V HFE2 (tTA-HepG2-
G99VHJV), or empty vector (tTA-HepG2-control) weremain-
tained in the absence of dox. Because the expression of HJV
mRNA in the absence of dox could not be turned off completely
in tTA-HepG2-HJV cells, as judged by qRT-PCR, tTA-HepG2-
control and tTA-HepG2-G99VHJV cells were used as the con-
trols in this study. The expression of HJV was induced by the
addition of dox to the medium 6 h before cells were incubated
with Neo FNIII 5–6 and BMP4. Cell lysates were collected 18 h
later to analyze the hepcidin mRNA and pSmad protein levels
by qRT-PCR and Western blot, respectively.
The addition of Neo FNIII 5–6 to cells suppresses BMP4-
stimulated hepcidin expression. Expression of HJV, but not
G99VHJV, increased hepcidinmRNA by about 3-fold (1 versus
4, Fig. 5A) and 1.8-fold (2 versus 5, Fig. 5A) without and with
addition of 5 ng/ml BMP4, respectively. Upon treatment with
both Neo FNIII 5–6 and BMP5, about a 70-fold decrease of
BMP4-induced hepcidin mRNA was detected in tTA-HepG2-
HJV cells (5 versus 6, Fig. 5A). In contrast, no significant change
was observed in tTA-HepG2 control (2 versus 3, Fig. 5A) and
G99VHJV (8 versus 9, Fig. 5A) cells under the same conditions.
These results are consistent with the finding that HJV is a BMP
co-receptor (13) and that Neo FNIII 5–6 disrupts the HJV-
neogenin complex that augments BMP signaling.
In agreement with the levels of hepcidinmRNA (Fig. 5A), the
addition of Neo FNIII 5–6 also prevented the induction of
pSmad signaling by BMP4 in tTA-HepG2-HJV cells but not in
tTA-HepG2-control or tTA-HepG2-G99V HJV cells (Fig. 5B).
The lack of inhibition in tTA-HepG2-control or tTA-HepG2-
G99VHJV cells suggests that Neo FNIII 5–6 does not affect the
BMP signaling in the absence of wild type HJV. Given the find-
ings that the HJV-neogenin interaction takes place at the
plasma membrane (24), that Neo FNIII 5–6 disrupts the inter-
action of HJV with full-length neogenin (supplemental Fig. 3),
and that HJV can simultaneously bind both BMP2 and neoge-
nin (26), these data suggest that the interaction between HJV
and neogenin after it reaches the cell surface is required for the
induction of BMP-signaling by BMP4.
To rule out the possibility that the suppressed BMP sig-
naling and hepcidin expression by Neo FNIII 5–6 is caused
by the altered HJV trafficking to the plasma membrane, the
effect of Neo FNIII 5–6 on cell surface HJV expression was
examined. BMP signaling is initiated upon BMP binding to
the BMP receptors on the cell surface (15). Our previous
studies indicate that knockdown of neogenin does not affect
HJV targeting to the plasma membrane (24). HJV-HepG2
cells were incubated in the presence or absence of Neo FNIII
5–6 for 18 h followed by flow cytometry analysis of cell sur-
FIGURE 5. Soluble neogenin suppresses BMP4-induced hepcidin expres-
sion only when HJV is expressed. A, qRT-PCR analysis of hepcidin mRNA.
tTA-HepG2 cells stably transfected with empty vector (control), HJV, or G99V
HJV were maintained in the absence of dox. At about 48 h after subculturing
into 12-well plates, cells were first incubated with MEM, 1 mM pyruvate, 1
NEAA, 1%FCS plus 2g/ml dox for 6 h to serum starve the cells and to induce
HJV expression. Cells were then incubated in the same medium containing
BMP4 at 0 or 5 ng/ml with or without 40 nMNeo FNIII 5–6 (Neo) for 18 h. Total
RNA was isolated followed by cDNA preparation and qRT-PCR analysis of
hepcidin and GAPDHmRNA. The hepcidin mRNA levels are expressed as the
amount relative to that ofGAPDH ineach specific sample. The results are from
four separate experiments and were assessed by one-way analysis of vari-
ance. The statistical significant differences relative to the corresponding con-
trols were determined by Tukey’s post test. *, p 0.05; ***, p 0.001. B, West-
ern blot analysis. Incubation of tTA-HepG2-control, -HJV, and -G99V HJV cells
with Neo FNIII 5–6 (Neo) and BMP4 was performed essentially the same as
described in A. Total cell lysates (L) were subjected to SDS-PAGE followed by
immunodetection of pSmad1/5/8 (pSmad), HJV, and-actin. This experiment
was repeated three timeswith consistent results.C, flowcytometry analysis of
cell surface HJV after incubationwith Neo FNIII 5–6. Control- and HJV-HepG2
cells were incubated with or without 40 nM Neo FNIII 5–6 for 18 h. Cells were
then detached from flasks with cell dissociation buffer and incubated with
affinity-purified rabbit anti-HJV antibody (4 g/ml) in Hanks’ buffer supple-
mentedwith 3% fetal bovine serum for 30min at 4 °C followed by incubation
with phycoerythrin-conjugated goat anti-rabbit IgG (1:500 dilution) in the
same buffer for 30 min at 4 °C. Flow cytometry analysis was performed on a
BD Biosciences FACSCalibur flow cytometer. Rabbit IgG and control-HepG2
cells were used as negative controls. The levels of cell surface HJV are
expressed as arbitrary units. The results are from three separate experiments
and themean values and the S.D. are presented. p values are calculated using
two-tailedStudent’s t test to compare thedifferencebetween theHepG2-HJV
cells incubated with (HJV/Neo FNIII 5–6) and without (HJV) Neo FNIII 5–6.
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face HJV (24). Consistent with the neogenin knockdown
study (24), Neo FNIII 5–6 did not significantly alter the cell
surface HJV levels compared with the corresponding control
(Fig. 5C). Together, these results indicate that Neo FNIII
5–6 suppresses BMP signaling and hepcidin expression by
disrupting the interaction between full-length neogenin and
HJV but not through its participation in HJV cleavage or by
affecting its cell surface localization.
Soluble Neogenin Suppresses Hepatic Hepcidin Expression in
Vivo—To determine whether the HJV-neogenin interaction is
physiologically significant in vivo, we examined the effect of
human Neo FNIII 5–6 on hepatic hepcidin expression in mice.
Both neogenin and HJV are highly conserved between species.
Our previous study showed that knockdown of neogenin in
C2C12 cells, a mouse myoblast cell line, suppresses the release
of transfected human HJV (6). Because the inhibition of HJV
release in HepG2 cells is an immediate process (data not
shown), purified Neo FNIII 5–6 at 3 mg/kg body weight was
intraperitoneally injected into wild type male 129EvSv mice (8
weeks old) at 16 and 24 h before the collection of liver tissues.
Control mice were injected with the same volume of carrier
buffer.We used qRT-PCR to examine the levels of hepatic hep-
cidin mRNA. Injection of Neo FNIII 5–6 significantly sup-
pressed hepcidin mRNA by40% (p 0.0071) (Fig. 6). These
results suggest that interaction of HJV with neogenin is
required for the induction of hepcidin expression in vivo.
DISCUSSION
In this study we characterized the role of neogenin in HJV-
regulated hepcidin expression. Results showed that both HJV
and neogenin were expressed in liver hepatocytes and evenly
detected throughout the liver tissues. Disruption of the inter-
action between HJV and neogenin by down-regulation of neo-
genin by siRNA or by the addition of a soluble neogenin frag-
ment that binds HJV markedly decreased BMP4-induced
hepcidin mRNA levels in HJV-expressing HepG2 cells.
Togetherwith the in vivo study using theHJV binding fragment
of neogenin (FNIII 5–6) to disrupt the interaction betweenHJV
and the full-length neogenin, our data support the idea that
HJV-neogenin interaction enhances BMP-mediated induction
of hepcidin expression.
To determine the role of neogenin in HJV-regulated hepci-
din expression, we examined the expression profiles ofHJV and
neogenin in the liver. A previous report using lacZ protein as an
indirect marker showed a selective expression of HJV, a critical
upstream regulator of hepcidin transcription (5, 9, 10), in the
hepatocytes around the portal triad (10). Here, using more
direct methods, we confirmed the predominant expression of
HJV in liver hepatocytes. But rather than a selective expression
of HJV in hepatocyte cells in the periportal zone (10), our
results indicate a uniform localization of both HJV mRNA and
protein in hepatocytes throughout the tissue. Distinct from
HJV, neogenin mRNA and protein were detected in all of the
liver cell populations with the hepatocytes as the predominant
source of neogenin. Thus, both HJV and neogenin are co-ex-
pressed in liver hepatocytes.
The significant inhibition of hepcidin expression by dis-
rupting the HJV-neogenin interaction in HJV-expressing
HepG2 cells was an unexpected result. Previous studies show
that the interaction of HJV with neogenin is required for HJV
release from hepatoma cell lines (HepG2 and Hep3B cells), a
myoblast cell line (C2C12 cells), and HEK293 cells (6, 17, 24).
Cellular HJV enhances the transcription of hepcidin through
the BMP-signaling cascade by acting as a BMP co-receptor
(13, 14), whereas the released soluble HJV is thought to serve
as a BMP antagonist to suppress BMP-induced hepcidin
expression through competition with membrane-associated
HJV for limited BMPs (14, 18, 20). In HepG2 cells, HJV
release constitutes the major pathway of cellular HJV turn-
over (17). Initially, we reasoned that blockage of HJV release
by neogenin knockdown or a soluble neogenin would en-
hance BMP signaling and BMP4-induced hepcidin expres-
sion. However, the profound suppression of BMP signaling
by both neogenin knockdown and treatment with Neo FNIII
5–6, but not by a furin convertase inhibitor that inhibits HJV
release, leads us to conclude that the HJV-neogenin interac-
tion is essential for the induction of BMP signaling and hep-
cidin expression in hepatocytes. Results from the further
studies of G99V HJV, a non-functional form of HJV that
causes juvenile hemochromatosis in humans (5), support
that neogenin functions to guide the induction of BMP sig-
naling and hepcidin expression only when it is associated
with the HJV that binds both full-length neogenin and BMPs.
FIGURE 6. Soluble neogenin suppresses hepatic hepcidin expression in
mice. Eight-week-old male 129EvSv mice were injected intraperitoneally
with purified neogenin FNIII 5–6 (Neo FNIII 5–6) at 3 mg/kg body weight or
the carrier buffer (Ctrl) twice at 8:30 amand3:30pmon the sameday. Injected
mice had free access to the regular rodent diet. At 24 h after the first injection,
animalswere euthanizedwhile under anesthesia. Liver tissueswere collected
for qRT-PCR analysis of hepcidin and GAPDHmRNA. The hepcidin mRNA lev-
els were calculated as the amount relative to that of GAPDH in each specific
sample andare expressedas theamount relative to the carrier buffer-injected
mice. Each group consisted of three mice. The mean values and the S.D. are
presented. p values are calculated using two-tailed Student’s t test to com-
pare the difference between the two groups.
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In contrast to HJV-HepG2 cells, we did not observe any sig-
nificant effect on hepcidin expression when HepG2 cells trans-
fected with empty vector or G99V HJV were incubated with
soluble neogenin. However, we detected a 2-fold decrease of
hepcidin expression when the endogenous neogenin in these
cells was knocked down. These results imply that neogenin
alone mildly enhances BMP signaling. Neogenin is a type I
transmembrane protein. Recent studies showed that the neo-
genin 388-amino acid cytoplasmic domain is involved in vari-
ous signal transduction pathways when associated with the
repulsive guidance molecules a (RGMa) (30–33). The RGM
family has three members (RGMa, RGMb, and RGMc). RGMc
is the ortholog of HJV in mice. Similar to HJV, both RGMa and
RGMb are glycosylphosphatidylinositol-linked proteins, bind
neogenin, and are BMP coreceptors. In contrast to HJV, RGMa
and RGMb are expressed primarily in the developing and adult
central nervous system in distinct,mostly non-overlapping pat-
terns (34–36). On the basis of the results in this study, we spec-
ulate that in the tissues that do not express HJV or RGMa or
RGMb, neogenin may function to maintain the basal level of
BMP signaling through its cytoplasmic domain. In the tissues
that express either RGMa or RGMb, neogenin may play a sim-
ilar role in the induction of BMP signaling as it does in the
presence of HJV.
In this and our previous studies (17), we observed an inter-
esting phenomenon. Both neogenin knockdown and treatment
with either neogeninwhole ectodomain or FNIII5–6 fragments
can suppress the HJV release from HJV-HepG2 cells. But only
the neogenin knockdown and neogenin whole ectodomain
treatment result in the accumulation of cellular HJV. Flow
cytometry analysis showed no significant change of cell surface
HJV, suggesting that the increased cellular HJV does not result
from theHJV accumulation at the cell surface. Immunofluores-
cence analysis revealed an increased accumulation of HJV in an
uncharacterized intracellular compartment when neogenin is
knocked down.3 As a result, we speculate that cellular HJV
accumulation may result from an altered HJV trafficking.
HJV release is negatively regulated by holo-transferrin and
iron (6, 19, 20). The release of HJV from both a myoblast cell
line and HepG2 cells depends on the interaction with neogenin
(6). Although both HJV and neogenin are expressed in skeletal
muscles and the liver (5, 6, 21), only the liver is the predominant
site of hepcidin expression (11, 12). On the basis of these obser-
vations and the results obtained in this study, we hypothesize
that the major function of hepatic neogenin is to augment the
HJV-enhanced hepcidin expression through the BMP signaling
pathway. We speculate that the major function of neogenin in
the skeletal muscles, the major site of HJV expression in the
body (5), is to mediate the release of HJV into circulation in
response to the body iron status, which indirectly modulates
the hepatic hepcidin expression.
In this study we found that the extent of inhibition of hepci-
din expression by disrupting the HJV-neogenin interaction is
independent of exogenous BMP4 ligand. Our findings are,
therefore, not in agreementwith the recent report showing that
knockdown of neogenin has no evident effect on hepcidin
expression in HJV-expressing cells (28). The basis for the dif-
ference between our results and theirs is not clear.
The BMP signaling cascade is initiated by ligand binding to
two type I receptors followed by recruitment of two type II
receptors to form heterotetramers. Ligand binding induces
phosphorylation of the type I receptor by the type II receptor,
which leads to phosphorylation of cytoplasmic receptor-acti-
vated pSmads. The receptor-activated Smads form hetero-
meric complexes with Smad4, the central mediator in BMP/
Smad signaling, which translocates from the cytoplasm to the
nucleus to initiate hepcidin gene transcription (37). We found
that the interaction with neogenin is required for cellular HJV
processing in our previous studies (17, 24) and that the disrup-
tion of the HJV-neogenin interaction suppresses BMP4-in-
duced hepcidin expression in this study. On the basis of these
observations, we hypothesize that neogenin may regulate BMP
signaling and hepcidin expression through several possible
mechanisms. First, neogenin could be directly or indirectly3 A.-S. Zhang and C. A. Enns, unpublished observations.
FIGURE 7. A model of neogenin in HJV-induced hepcidin expression in
hepatocytes. A, HJV-neogenin is required for the proper assembly of HJV-
BMP ligand-BMPR I/BMPR II complex to initiate the BMP signaling and to
induce hepcidin expression. B, disruption of HJV-neogenin interaction either
by neogenin (Neo) knockdown or by soluble neogenin (sNeo) leads to the
formation of the aberrant and non-functional HJV-BMP ligand-BMPR I com-
plex.FNIII 5, neogenin fibronectin type III 5domain. FNIII 6, neogenin fibronec-
tin type III 6 domain. BMPRI, type I BMP receptor. BMPRII, type II BMP receptor.
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involved in the proper assembly of the BMP receptor tetramer
upon the binding of BMP ligand in the presence of HJV. In this
scenario, disruption of the HJV-neogenin interactions at the
cell surface will lead to the aberrant assembly of BMP receptors
withHJVupon theBMP ligand binding and consequently result
in the lack of BMP-signaling induction (Fig. 7). Second, neoge-
nin could inhibit the degradation of BMP receptors once asso-
ciatedwithHJV. Third, the signal transductionmediated by the
neogenin cytoplasmic domain may play an important regula-
tory role in the induction of hepcidin expression. Understand-
ing the requirement for neogenin in the activation of hepcidin
transcription will be the subject of future research.
In addition, two recent studies indicate a critical role of
BMP6 in iron homeostasis, presumably through HJV (38, 39).
Kautz et al. (40) showed that similar to the hepatic hepcidin
expression profile, BMP6 expression in the liver is positively
regulated by dietary iron. Therefore, it will also be important to
elucidate the role of neogenin in BMP6-regulated hepcidin
expression.
In summary, we demonstrated that both HJV and neogenin
are uniformly expressed in liver hepatocytes with no distinct
gradient of distribution. Our results support the notion that in
the presence of HJV, the induction of hepcidin expression by
BMP4 requires neogenin.
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